Filing Summary
Company: Pliant Therapeutics, Inc. (Nasdaq: PLRX)
Filing: Form 8-K filed July 2, 2021, reporting matters from the June 29, 2021 Annual Meeting of Stockholders.
Business Context and Reporting Period
The filing reports the results of the Company’s annual stockholder meeting held June 29, 2021. As of the April 30, 2021 record date, 35,875,918 shares of common stock were outstanding and entitled to vote. The filing contains no quarterly or annual financial statements.
Key Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margin, debt, liquidity, operating guidance, or other financial performance metrics.
Material Matters and Vote Results
- Stockholders elected Class I directors Hoyoung Huh, M.D., Ph.D., Neil Exter, MBA, and David Pyott, MA, MBA, to three-year terms expiring at the 2024 Annual Meeting.
- Votes for and against the director nominees were: Hoyoung Huh—13,651,371 for and 5,881,007 withheld; Neil Exter—13,663,543 for and 5,868,835 withheld; David Pyott—19,517,150 for and 15,228 withheld.
- Broker non-votes for the director election totaled 4,874,323 shares. The filing text repeats this statement but does not provide separate broker non-vote totals by nominee.
- Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021, with 24,376,650 votes for, 28,928 against, and 1,123 abstentions.
- No other matters were submitted to or voted on.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no management guidance, outlook, risk discussion, contingencies, or unusual financial items. The principal governance item was the election of three directors and ratification of the independent auditor.
Investor Verification Points
- Verify the director election terms and current board composition in subsequent filings.
- Confirm Deloitte & Touche LLP’s appointment and review subsequent filings for any changes in the independent auditor relationship.
- Consult the Company’s April 30, 2021 definitive proxy statement for detailed proposal descriptions, voting procedures, and ownership or governance information not included in this 8-K.
- Use the Company’s periodic reports for financial performance, cash runway, liquidity, debt, clinical-program updates, and risk factors, none of which are covered here.